COMPASS Pathways, a mental health treatment company, received the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit healthcare researcher, been given the designation to carry on its testing of psilocybin being a treatment for main depressive disorder.The thoughts expressed will